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Introduction
Clostridium difficile  (CD) is a gram positive, anaerobic 
and spore-forming bacillus [1]. CD  causes a toxin-mediated 
colitis by expressing the toxin A and toxin B [2, 3] that are 
encoded by the tcdA and tcdB genes. These toxins lead to 
intercellular gap cytoskeleton destruction that results in cell 
death via apoptosis and necrosis [3] and in turn to pseudo-
membranous colitis [4, 5]. Sometimes a binary Clostridium 
difficile toxin (CDT) is expressed in hypervirulent CD 
species [2, 5]. The A+B+CDT-genotype was identified in 
87.13% of cases in a brief study made in Shanghai (China) 
[6]. This microorganism may be transmitted within a com-
munity, causing a community-acquired Clostridium difficile 
infection (CDI), or within the hospitals, leading to a health-
care-associated CDI [7-10]. A study conducted in Spain re-
vealed that 16% of the CDI were acquired before Intensive 
Care Unit (ICU) admission or before hospital admission 
and are commonly more severe [11]. The incidence of CDI 
is decreasing over the last 10 years in Spain [11]. A study 
showed that less than 1% of patients developed healthcare-
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Abstract
Background: Clostridium difficile (CD) infection is widespread throughout the world, showing an increased incidence over the recent years and may 
cause severe forms of disease. This infection most commonly affects patients whom were administered antibiotics. An increased resistance to commonly 
used antibiotics is associated with Clostridium difficile infection (CDI). CD has a generally recognized infectious potential on a clinical ground. CDI is 
unpleasant and may sometimes cause serious bowel disorders that are usually treated with another course of antibiotics. The evolution of CD infection 
depends on the individual characteristics of the patient along with risk factors, associated diseases as well as the particularities of the recommended 
treatment. However, even under the conditions of a correct and complete treatment the risk of the disease relapse is estimated to occur depending on 
risk factors. Many clinical instruments that are designated for the purposes to treat non-infectious diseases can be useful in estimating the severity of an 
infection. This review is important for understanding the abusive and irrational prescription of various groups of antibiotics, often unjustified, including 
the ones used in the treatment of an infection with SARS-CoV-2.
Conclusions: These infections mostly occur in people aged 65 and older that receive medical care, including antibiotics administration, people with a 
long-term hospital stay, people with a weakened immune system or with a previous CD infection. The following measures, in order to reduce the risk of 
CDI in patients, should be considered: hand hygiene, avoidance of unnecessary administration of antibiotics – the antibiotic treatment is recommended 
only if it is prescribed by an experienced specialist, avoidance of unnecessary administration of drugs that reduce gastric acidity, because it favors the 
invasion of the gastrointestinal tract with CD.
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associated CDI, but a high risk of recurrence and complica-
tions was associated with a long ICU stay [12].
On the other hand, the incidence and severity of 
Clostridium difficile-associated diarrhea (CDAD) have in-
creased in the United States of America (USA) [13].  Up 
to 50% of newborns have a CDI in the first 10 days of 
life, and up to 70% in the first 30 days of life [9]. Other 
sources inform that up to 35% of infants had CDI within 
the ICU [10]. It is reported that CD causes 12-12.1% [14, 
15] or 21-22.4%, according to another source, [16] of all 
healthcare-associated infections. The incidence of  CDAD 
in hospitalized patients ranges between 3-29% [17, 18]. The 
prevalence for CDI in India was 5.6-15.4% [19], in Kuwait – 
6.42% [20].
There is a seasonal incidence for CDI, being higher in 
March-June then in October-December in the Northern 
Hemisphere and Asia [21]. Approximately 1/3 of the pa-
tients who develop antibiotic-associated diarrhea will be-
come infected with CD [22]. Almost one-third of hospital-
associated CD infections referred to asymptomatic adult 
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carriers [9] in which the mortality incidence ranges between 
3.4-15.1% [23].
Bacterial antibiotic resistance is a growing global con-
cern [24], this fact being also observed for the CD occurence 
[25]. ICU patients have a higher risk to develop CDI [26]. 
Antibiotic-associated diarrhea (AAD) is present in 25-30% 
of the patients who take antibiotics, which is defined as 3 or 
more loose stools over 24 h [27].
The purpose of this study is to identify the most impor-
tant risk factors and treatment options that are currently 
available for a CDI. The PubMed database was used in or-
der to identify the relevant scientific articles. The following 
keywords were used: “Clostridium difficile in the intensive 
care unit”, March 7, 2020. The study was carried out by ana-
lyzing the 100 scientific articles that were identified using 
the PubMed search engine, after excluding the scientific 
articles that were published before 2015 and were irrel-
evant (42 articles), finally 58 scientific articles remained. 13 
sources were identified in a non-systematic manner after 
using the keywords “Clostridium difficile diagnostic”. The 
study was performed on the prevalence, incidence and re-
gional specificity of CD management including the risk fac-
tors, treatment options and the prevention methods within 
the ICU.
Results and discussion
Risk factors
The present study identified the following risk factors 
that were mentioned in one or more sources that were as-
sociated with the ICU:
1. Proton pump inhibitors [1, 3, 27-33]. One of the litera-
ture sources proves it wrong [14].
2. The use of some antibiotics is proven to be the leading 
cause of CDI [1, 14, 33-37] as well as administration 
of antimicrobial drugs [38] or long-term and mul-
tiple use of antimicrobials [13, 39, 40]. Clindamycin, 
cephalosporins, penicillins and fluoroquinolones are 
the antibiotics that commonly increase the risk of a 
CDI [3].
3. Advanced age (>65 years) [1, 3, 27, 39] and a long hos-
pital stay [1, 3, 27, 39, 41].
4. Healthy adults, peripartum women and young chil-
dren that are admitted to hospitals are the most inci-
dent carriers of CD [42].
5. Chemotherapy [3, 27] and H2 receptor blockers [3].
6. Several comorbidities or comorbidity-related condi-
tions, such as an increased serum creatinine level (an 
indicator of renal dysfunction) at the time of ICU 
admission [13, 14], admission to a neurological ICU 
[14], immunocompromising conditions, inflamma-
tory bowel disease (IBD) [13], diabetes mellitus [18, 
27], malignant neoplasms [13, 38], cirrhosis, hypoal-
buminemia [36], fever, metabolic disorders [40].
7. Surgical intervention is a known risk factor for CDI, at 
the same time a known treatment option for patients 
with severe CDI [44], preoperative acute renal failure 
and postoperative acute hyperglycemia are regarded 
as isolated risk factors [45]. 
8. Chronic obstructive pulmonary disease (COPD) was 
positively associated with CDI in trauma/surgery pa-
tients compared with medical patients [41].
9. Positive toxin test, because it may not always indicate 
a CDI [43].
In addition, were identified unexpected neutral factors:
1. Trauma doesn’t increase the CDI incidence [46, 47].
2. Metronidazole was not associated with a high CDI risk 
[48].
Prevention, diagnosis and treatment methods
The prevention methods involve hand hygiene and re-
duction of enviormental contamination [33, 49, 50]. Most 
sources attest that Chlorhexidine has no effect on the inci-
dence of CDI [51], [52], while another source states that it is 
unclear [39] and only one source has reported a decreasing 
incidence, with 7% [53]. The probiotics usage is not a widely 
used preventive measure [33].
The diagnostic methods include the cell cytotoxicity test 
(CCT), which is the measurement of toxins in the feces or 
the cytotoxigenic culture (CC) study [54]. RT-PCR is a use-
ful method in order to identify the CD toxins in the stool, 
though a very expensive one  compared to other methods 
[5]. Nucleic acid amplification test is used in order to iden-
tify the CD strains [33, 54] with Glutamate dehydrogenase 
tests [54]. 
A strategy for identifying patients with a high risk for 
CDI is proven to be efficient for reducing the mortality rate 
in the ICU [55]. Therefore, the physiologic scores used for 
the assessment of the patients in the ICU may be quite use-
ful – Acute physiology and chronic health evaluation II 
(APACHE II) [56-60], APACHE III [61], APACHE IV [34], 
Zar’s score [23, 62, 63] and Charlson comorbidity index 
(CCI) [38, 64-66].
The treatment methods include basic antimicrobial pro-
grams and antimicrobial management, the usage of antibiot-
ics (e.g. vancomycin) [67]. The first-line treatment is repre-
sented by metronidazole administration, while the second-
line treatment is represented by administration of vancomy-
cin or fidaxomycin [3, 33]. Mild or moderate CDI should be 
treated with oral vancomycin [3] or metronidazole [3, 40, 
48, 68], other studies reported no effectiveness for metro-
nidazole [33]. Severe cases were treated with intravenous/
ileostoma-administered vancomycin [68]. Vancomycin is 
administered in 48.3% of cases, whereas metronidazole is 
administered in 34.5% of cases according to one study [69]. 
Other sources report that vancomycin usage should be re-
vised [67]. Recent new treatment options involve fecal mi-
crobiota transplant [3] which was reported as an effective 
treatment option [70, 71]. Bezlotoxumab – antibody specific 
for Clostridium difficile is proven to be effective in the treat-
ment of this infection [33].
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Conclusions
1. Clostridium difficile remains an actual controversial is-
sue according to the articles reviewed within this study. The 
present study concluded that the most reported risk factors 
were the following:
- Antibiotic usage (12 sources);
- Proton pump inhibitors (9 sources);
- Long duration of hospitalization (5 sources);
- Advanced age (4 sources).
2. No adequate or sufficiently proven preventive mea-
sures were found, the only exception accounts for the 
reduction of in-hospital circulation of different doc-
tors and visitors.
3. The following useful tools, for the diagnostic act, were 
identified – APACHE scales, CCI and the Zar’s score. 
The most efficient, though the most expensive, clinical 
test is RT-PCR.
4. The most efficient and wide-spread treatment options 
were as follows:
- Oral vancomycin and metronidazole given in mild 
cases, as well as administered through the intravenous/
ileostoma route in severe cases;
- Fecal microbiota transplant.
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